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Purpose: The purpose was to summarize US pre-
scribing information for teriﬂunomide in the treatment
of patients with relapsing forms of multiple sclerosis
(RMS), with reference to clinical efﬁcacy and safety
outcomes.
Methods: In September 2012, the US Food and
Drug Administration granted approval for the use of
teriﬂunomide, 14 mg and 7 mg once daily, to treat
RMS on the basis of the results of a Phase II study and
the Phase III TEMSO (Teriﬂunomide Multiple Scle-
rosis Oral) trial. After recent updates to the prescrib-
ing information (October 2014), key ﬁndings from
these and 2 other Phase III clinical trials, TOWER
(Teriﬂunomide Oral in People With Relapsing Multi-
ple Sclerosis) and TOPIC (Oral Teriﬂunomide for
Patients with a First Clinical Episode Suggestive of
Multiple Sclerosis), and practical considerations for
physicians are summarized.
Findings: Teriﬂunomide, 14 mg and 7 mg, signiﬁ-
cantly reduced mean number of unique active lesions
on magnetic resonance imaging (MRI; P o 0.05 for
both doses) in the Phase II study. In the TEMSO and
TOWER studies, the 14-mg dose of teriﬂunomide
signiﬁcantly reduced annualized relapse rate (31%
and 36% relative risk reduction compared with
placebo, respectively; both P o 0.001) and risk of
disability progression sustained for 12 weeks (hazard
ratio vs placebo 0.70 and 0.69, respectively; both Po
0.05). The 7-mg dose signiﬁcantly (Po 0.02) reduced
annualized relapse rate in both studies, although the
reduction in risk of disability progression was not
statistically signiﬁcant. Teriﬂunomide treatment was
also associated with signiﬁcant efﬁcacy on MRI
measures of disease activity in TEMSO; both doses
signiﬁcantly reduced total lesion volume and number
of gadolinium-enhancing T1 lesions. TOPIC evaluated
patients with a ﬁrst clinical event consistent with acute
demyelination and brain MRI lesions characteristic of
multiple sclerosis. More patients were free of relapse2366in the teriﬂunomide 14-mg and 7-mg groups than in
the placebo group (P o 0.05 for both comparisons).
In safety data pooled from the 4 studies, adverse
events occurring inZ2% of patients andZ2% higher
than in the placebo group were headache, alanine
aminotransferase increase, diarrhea, alopecia (hair
thinning), nausea, paresthesia, arthralgia, neutrope-
nia, and hypertension. Routine monitoring procedures
before and on treatment are recommended to assess
potential safety issues. Women of childbearing poten-
tial must use effective contraception and, in the event
of pregnancy, undergo an accelerated elimination
procedure to reduce plasma concentrations of teri-
ﬂunomide.
Implications: Clinical evidence suggests that teri-
ﬂunomide is an effective therapeutic choice for pa-
tients with RMS, both as an initial treatment and as
an alternative for patients who may have experienced
intolerance or inadequate response to a previous or
current disease-modifying therapy. (Clin Ther.
2015;37:2366–2380) & 2015 The Authors. Published
by Elsevier HS Journals, Inc.
Key words: efﬁcacy, multiple sclerosis, oral disease-
modifying therapy, safety, teriﬂunomide.
INTRODUCTION
Teriﬂunomide* is a once-daily oral immunomodulator
with anti-inﬂammatory properties, licensed for the treat-
ment of patients with relapsing forms of multiple
sclerosis (RMS).1 Teriﬂunomide received US Food and
Drug Administration (FDA) approval in September 2012Volume 37 Number 10
A.E. Millerand was the second oral disease-modifying therapy
to be licensed for RMS. Three oral agents are now
available, including ﬁngolimod†,2 and dimethyl
fumarate‡,3 which provide an alternative to the inject-
able therapies, interferon-β and glatiramer acetate,
that have some limitations for tolerability, efﬁcacy,
and patient acceptability.
The exact mechanism by which teriﬂunomide exerts
its therapeutic effect in MS is not fully understood, but
it likely involves a reduction in the number of activated
lymphocytes that enter the central nervous system.
Teriﬂunomide selectively and reversibly inhibits dihy-
droorotate dehydrogenase, a key mitochondrial en-
zyme in de novo pyrimidine synthesis that is required
by rapidly dividing lymphocytes. Blocking dihydroor-
otate dehydrogenase results in a reversible cytostatic
effect that limits the expansion of stimulated T and B
cells thought to be responsible for the damaging
inﬂammatory process associated with MS. In contrast,
resting and slowly dividing cells, including lympho-
cytes and nonlymphoid cells, rely on the pyrimidine
salvage pathway to meet their pyrimidine demand.
Because this pathway is not affected by teriﬂunomide,
basic homeostatic functions of resting and slowly
dividing cells appear to be preserved, and immune
cells remain available for immune surveillance.4,5
Teriﬂunomide is the active metabolite of leﬂuno-
mide§, a drug licensed for the treatment of active
rheumatoid arthritis since 1998.6 The extensive
clinical experience with leﬂunomide (42.58 million
patient-years of cumulative exposure) has informed
the teriﬂunomide US prescribing information about its
safety proﬁle. However, note that leﬂunomide was
only evaluated in patients with rheumatoid arthritis,
whose condition is often confounded by comorbidities
and concomitant medications.
Teriﬂunomide is approved in 450 countries and,
as of August 2014, 30,000 patients were treated
with teriﬂunomide in clinical trials and postmarketing
settings worldwide.
This review summarizes key data that supported
FDA approval of teriﬂunomide, 14 mg and 7 mg, and
informed recommendations in the US prescribing
information. The prescribing recommendations are†Trademark: Gilenyas (Novartis, East Hanover, New Jersey).
‡Trademark: Tecﬁderas (Biogen Idec, Cambridge,
Massachusetts).
§Trademark: Aravas (sanoﬁ-aventis, Bridgewater, New Jersey).
October 2015also reviewed, with the aim of providing a practical
summary for US clinicians who wish to prescribe
teriﬂunomide for patients with RMS.
KEY FINDINGS FROM CLINICAL TRIALS
The FDA approval of teriﬂunomide in September
2012 was based primarily on safety and efﬁcacy data
from 2 randomized, placebo-controlled clinical trials
that evaluated the teriﬂunomide 14-mg and 7-mg
once-daily doses in patients with RMS: the 108-
week Phase III TEMSO (Teriﬂunomide Multiple
Sclerosis Oral) study (Study 1; NCT001345637) and
a 36-week Phase II study (Study 4; NCT014870968).
In October 2014, the teriﬂunomide prescribing
information was updated to include data from 2
additional randomized, placebo-controlled Phase III
trials: TOWER (Teriﬂunomide Oral in People
With Relapsing Multiple Sclerosis; Study 2;
NCT007518819) in patients with RMS, and TOPIC
(Oral Teriﬂunomide for Patients with a First Clinical
Episode Suggestive of Multiple Sclerosis; Study 3;
NCT0062270010) in patients with a ﬁrst demyelin-
ating event consistent with MS (Table I).
Clinical and Magnetic Resonance Imaging
Outcomes
Phase II Study
The 36-week Phase II study of 179 patients with
clinically conﬁrmed MS11 and a history of relapse
reported positive outcomes with teriﬂunomide on
magnetic resonance imaging (MRI) variables. The
mean number of unique active lesions per scan was
signiﬁcantly lower in the teriﬂunomide 14-mg and
7-mg groups (0.98 and 1.06 lesions/scan, respectively)
than in the placebo group (2.69 lesions/scan;
P ¼ 0.0052 and P ¼ 0.0234, respectively) (Figure 1).1,8
TEMSO
TEMSO1,7 enrolled 1088 patients with active dis-
ease (baseline Expanded Disability Status Scale [EDSS]
scores r5.5, and at least 2 clinical relapses in the
previous 2 years or 1 relapse during the preceding
year) who met the McDonald 2001 criteria12 for MS
and had a relapsing clinical course with or without
progression. The majority of patients enrolled (91%)
had relapsing-remitting MS, with the remainder
having a progressive form of MS with relapses.
Teriﬂunomide 14 mg signiﬁcantly reduced the risk
of conﬁrmed disability progression sustained for2367
Table I. Overview of placebo-controlled trials of teriflunomide
Study Study Population Study Design Treatment Arms* Main End Points
Phase II Clinically deﬁnite MS Randomized (1:1:1),
double-blind, placebo-
controlled
Teriﬂunomide 14 mg/d
(n ¼ 57)
Primary
Aged 18–65 years
Duration 36 weeks
Teriﬂunomide 7 mg/d
(n ¼ 61)
Number of combined unique
active lesions per MRI
scan
EDSS score r6
Placebo (n ¼ 61) Secondary
2 relapses in past 3 years;
1 relapse in past year
Other MRI measures†
Annualized relapse rate
Disability progression
TEMSO (Phase III) McDonald criteria (2001)
for MS with relapsing
course  progression
Randomized (1:1:1),
double-blind, placebo-
controlled
Teriﬂunomide 14 mg/d
(n ¼ 358)
Primary
Aged 18–55 years Duration 108 weeks
Teriﬂunomide 7 mg/d
(n ¼ 365)
Annualized relapse rate
EDSS score r5.5 Placebo (n ¼ 363)
Secondary
Z2 clinical relapses in
previous 2 years or Z1
relapse in past year
Conﬁrmed disability
progression sustained
Z12 weeks
No relapse in 60 days before
random assignment
MRI total lesion volume
Number of Gd-enhancing
lesions on T1-weighted
images
TOWER (Phase III) McDonald criteria (2005)
for MS with relapsing
course  progression
Randomized (1:1:1),
double-blind, placebo-
controlled
Teriﬂunomide 14 mg/d
(n ¼ 370)
Primary
Aged 18–55 years Duration up to
40 months
Teriﬂunomide 7 mg/d
(n ¼ 407)
Annualized relapse rate
EDSS score r5.5 Placebo (n ¼ 388)
Secondary
Z2 clinical relapses in
previous 2 years or Z1
relapse in past year
Conﬁrmed disability
progression sustained
Z12 weeks
No relapse in 30 days before
random assignment
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October 201512 weeks compared with placebo (as measured byZ1-
point increase from baseline EDSS scorer5.5 or a 0.5-
point increase for those with a baseline EDSS score
45.5; P ¼ 0.028; hazard ratio ¼ 0.70) (Figure 2). At
week 108, the estimated percentage of patients with
12-week sustained disability progression with the use
of the Kaplan-Meier method was 20.2% and 27.3%,
in the teriﬂunomide 14-mg and placebo groups,
respectively. The 14-mg dose also signiﬁcantly re-
duced annualized relapse rate (ARR) by 31%
(P ¼ 0.0005) compared with placebo (Figure 3),
and the majority of patients (56.5%) remained
relapse-free at week 108 compared with the 45.6%
of patients that received placebo (Table II).1
Teriﬂunomide 7 mg also signiﬁcantly reduced
ARR by 31% (P ¼ 0.0002) with 53.7% of patients
remaining relapse free (Figure 3). However, the 7-mg
dose did not have a signiﬁcant effect on the risk of
disability progression (P ¼ 0.084) compared with
placebo (Table II, Figure 2).
The effect of teriﬂunomide on MRI variables was
also assessed in TEMSO.1,7,13 Signiﬁcant dose-
dependent improvements with teriﬂunomide over pla-
cebo were seen in change from baseline in total lesion
volume (the key MRI end point) and number of
gadolinium-enhancing T1 lesions per scan (Table II
and Figure 4).
A post hoc analysis of TEMSO found that the
efﬁcacy of teriﬂunomide on ARR was consistent
across a range of prespeciﬁed patient subgroups
deﬁned by sex, age, prior MS therapy, and baseline
disease activity.1,14
TOWER
TOWER1,9 included 1165 patients who met the
McDonald 2005 criteria15 for MS and had a relapsing
clinical course (with or without progression). Most
(98%) patients had relapsing-remitting MS, and the
remaining 2% had a progressive form of MS with
relapses.
A signiﬁcant reduction in the risk of disability
progression sustained for 12 weeks (P ¼ 0.044; hazard
ratio ¼ 0.69) was observed in the teriﬂunomide 14-mg
group compared with placebo; at week 108, an
estimated 15.8% of patients in the teriﬂunomide 14-
mg group had 12-week sustained disability progression,
compared with 19.7% in the placebo group (Figure 2).
Teriﬂunomide 14 mg signiﬁcantly reduced ARR by
36% (P ¼ 0.0001) (Figure 3), and at week 108, 57.1%2369
64% reduction 
P = 0.005
61% reduction 
P = 0.023
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Figure 1. Effect of teriflunomide treatment on
MRI-defined unique active lesions in
the Phase II study of teriflunomide.
MRI ¼ magnetic resonance imaging.
Clinical Therapeuticsof patients treated with teriﬂunomide 14 mg were free
from relapse, compared with 46.8% of patients given
placebo (Table II). Teriﬂunomide 7 mg signiﬁcantly
reduced ARR by 22% compared with placebo (P ¼
0.0183) (Figure 3), but it had no signiﬁcant effect on 12-
week sustained disability progression (Table II).
Teriﬂunomide treatment reduced ARR in a post hoc
analysis of prespeciﬁed patient subgroups deﬁned by sex,
age, prior MS therapy, and baseline disease activity.114 mg vs placebo: HR 0.70, P = 0.028
7 mg vs placebo: HR 0.76, P = 0.084 
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Figure 2. Time to disability progression sustained for
(B) studies. Modified intent-to-treat populati
HR was estimated with the use of a Cox propo
the log-rank test. HR ¼ hazard ratio. Adapte
2370TOPIC
In the TOPIC study, patients (N ¼ 614) had a ﬁrst
acute or subacute clinical event consistent with de-
myelination that occurred within 90 days of being
randomly assigned, with Z2 T2 lesions Z3 mm in
diameter on MRI, and were treated for up to 108
weeks. The proportion of patients free of relapse was
greater in the teriﬂunomide 14-mg (72.2%; Po 0.05)
and 7-mg (70.5%; P o 0.05) groups than in the
placebo group (61.7%).1,10Safety Profile and Tolerability
Safety proﬁle and tolerability data included in the US
prescribing information are based on a pooled analysis
of data from 2047 patients treated with teriﬂunomide in
the studies discussed in the sections above. The most
frequent adverse events in patients receiving teriﬂuno-
mide (occurring in Z2% of patients and Z2% above
the rate in patients receiving placebo) were headache,
alanine aminotransferase (ALT) increase, diarrhea, alo-
pecia (hair thinning), nausea, paresthesia, arthralgia,
neutropenia, and hypertension (Table III).1 ALT
increase was the event most frequently associated with
treatment discontinuation in the pooled clinical studies,
with 2.6 % and 3.3 % of patients discontinuing in the
teriﬂunomide 14-mg and 7-mg groups, respectively,
compared with 2.3% of patients in the placebo group.1.7%
.3%
.2%
Teriflunomide 14 mg
Teriflunomide 7 mg
Placebo
108
160
178
175
19.7%
15.8%
21.1%
14 mg vs placebo: HR 0.69, P = 0.044
7 mg vs placebo: HR 0.96, P = 0.762
TOWER
Weeks
388 354 325 295 271 241 195 156 128 83
406 375 337 314 286 248 202 163 114 77
370 340 310 286 267 245 211 162 124 87
40
0
10
20
30
0 12 24 36 48 60 72 84 96 108
12 weeks during the TEMSO (A) and TOWER
on. Kaplan-Meier estimates for time-to-event data.
rtional hazards model; P value was determined with
d with permission.7,9
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Figure 3. Annualized relapse rates in the TEMSO (A) and TOWER (B) studies. Modified intent-to-treat
population. Adapted with permission.7
A.E. MillerHepatic Events
In clinical trials, if ALT increase was 43 times
the upper limit of normal on 2 consecutive tests,
teriﬂunomide treatment was to be discontinued and
patients to undergo an accelerated elimination proce-
dure. ALT 43 times the upper limit of normal
occurred in 6.2% and 5.8% of patients receiving
teriﬂunomide 14 mg and 7 mg, respectively, and
3.8% of patients receiving placebo. Most elevations
occurred within the ﬁrst year of treatment, and
one-half of the cases returned to normal levels without
stopping teriﬂunomide treatment.1
Pregnancy
On the basis of animal studies, teriﬂunomide may
be associated with teratogenicity. Fetal malforma-
tions were observed in pregnant rats and rabbits
administered oral teriﬂunomide during organogenesis.
In studies in which teriﬂunomide was administered to
rats during gestation and lactation, decreased growth,
eye and skin abnormalities, and incidences of
limb malformations were observed. Teriﬂunomide is
therefore contraindicated in pregnant women and
women of childbearing potential who are not using
reliable contraception. Although teriﬂunomide was
positive in vitro in a chromosomal aberration
assay in human lymphocytes at concentrations higher
than exposure in clinical studies, other nonclinical
studies found no evidence of genotoxicity, mutagenesis,
or carcinogenesis.1October 2015White Blood Cells
Mean reductions in white blood cell counts
(mainly lymphocytes and neutrophils) of 15%
were observed in a pooled analysis of placebo-
controlled trials. These decreases occurred during
the ﬁrst 6 weeks of teriﬂunomide initiation and
persisted during treatment, although mean absolute
counts remained within the normal range for most
patients.1
Infections and Malignancies
No overall increase in the risk of serious infections was
observed in patients treated with teriﬂunomide 14 mg
(2.7%) or teriﬂunomide 7 mg (2.2%) compared with
placebo (2.2%), and no increase in the incidence of
malignancies and lymphoproliferative disorders was re-
ported in the clinical studies.1 Because cases of tuberculosis
were observed in clinical studies with teriﬂunomide,
patients should be screened for latent tuberculosis
infection and should be treated in case of a positive
result, before initiation of teriﬂunomide treatment.
Blood Pressure
Increases in blood pressure were observed in
patients who received teriﬂunomide in clinical studies,
with mean increases of 2.7 mm Hg (teriﬂunomide
14 mg) and 2.3 mm Hg (teriﬂunomide 7 mg) in
systolic blood pressure and o2 mm Hg in diastolic
blood pressure in either group; the mean changes from
baseline in the placebo group were –0.6 mm Hg2371
Table II. Clinical and MRI outcomes from the TEMSO and TOWER studies
TEMSO TOWER
Teriﬂunomide
14 mg
(n ¼ 358)
Teriﬂunomide
7 mg
(n ¼ 365)
Placebo
(n ¼ 363)
Teriﬂunomide
14 mg
(n ¼ 370)
Teriﬂunomide
7 mg
(n ¼ 407)
Placebo
(n ¼ 388)
Clinical results
Annualized relapse rate
(primary end point)
0.369 0.370 0.539 0.319 0.389 0.501
P value 0.0005 0.0002 o0.0001 0.0183
Relative risk
reduction vs
placebo, %
31 31 — 36 22
Patients remaining
relapse-free at week
108, %
56.5 53.7 45.6 57.1 58.2 46.8
Patients with disability
progression at week
108, %
20.2 21.7 27.3 15.8 21.1 19.7
P value 0.028 0.084 0.044 0.762
Hazard ratio 0.70 0.76 — 0.69 0.96 —
MRI results
Median change from
baseline in total
lesion volume*
(mL) at week 108
0.345 0.755 1.127 — — —
P value 0.0003† 0.0317†
Mean number of Gd-
enhancing T1
lesions per scan
0.261 0.570 1.331 — — —
P value o0.0001 o0.001
Gd ¼ gadolinium; MRI ¼ magnetic resonance imaging.
*Total lesion volume: sum of total volume of T2 lesion component and T1-hypointense lesion component measured by MRI.
†Determined with cubic root-transformed data for total lesion volume.
Clinical Therapeutics(systolic) and –0.3 mm Hg (diastolic). Hypertension
was reported as an adverse event in 4.3% and 3.1%
of patients treated with teriﬂunomide 14 mg or 7 mg,
respectively, compared with 1.8% for placebo.1
Four cardiovascular deaths (3 sudden deaths and
1 myocardial infarction in a patient with a history of
hyperlipidemia and hypertension) were reported among
2600 patients exposed to teriﬂunomide in the clinical
development program. These deaths occurred during
open-label extension studies, 1 to 9 years after initiation2372of teriﬂunomide treatment, and no relation between
teriﬂunomide and cardiovascular death was established.
In addition, no evidence was found that teriﬂunomide
caused clinically signiﬁcant prolongation in the QT inter-
val in an ECG study performed in healthy subjects.1,16
Peripheral Neuropathy
Peripheral neuropathy, including both polyneurop-
athy and mononeuropathy (eg, carpal tunnel syn-
drome), occurred more frequently in patients treatedVolume 37 Number 10
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Figure 4. Key MRI outcomes from the TEMSO study. (A) Median change in total lesion volume from baseline.
(B) Mean number of Gd-enhancing lesions per T1-weighted scan. Gd ¼ gadolinium; TEMSO ¼
Teriflunomide Multiple Sclerosis Oral.
A.E. Millerwith teriﬂunomide than in patients taking placebo.
The incidence of peripheral neuropathy conﬁrmed by
nerve conduction studies was 1.9% (17 patients) and
1.4% (13 patients) in patients receiving teriﬂunomide
14 mg and 7 mg, respectively, compared with 0.4% (4
patients) receiving placebo. Treatment was discontin-
ued in 5 patients receiving the 14-mg dose and 3
patients receiving the 7-mg dose; 5 patients recovered
after treatment discontinuation.Table III. Adverse events during placebo-controlled terifl
Adverse Event
(% of patients)
Teriﬂunomide 14 mg
(N ¼ 1002)
Headache 16
ALT increase 15
Diarrhea 14
Alopecia 13
Nausea 11
Paresthesia 9
Arthralgia 6
Neutropenia 6
Hypertension 4
ALT ¼ alanine aminotransferase.
*Reported inZ2% of patients in at least 1 teriﬂunomide arm, an
than the placebo group, in the Phase II, TEMSO, TOWER, and
October 2015PRACTICAL CONSIDERATIONS FOR
CLINICIANS PRESCRIBING TERIFLUNOMIDE
Clinicians wishing to initiate teriﬂunomide therapy in
patients with RMS need to be aware of certain
requirements for routine assessment of patients before
initiation of therapy and for further monitoring during
treatment. These requirements are discussed in more
detail in the sections below and are summarized in
Table IV.unomide trials*
Teriﬂunomide 7 mg
(N ¼ 1045)
Placebo
(N ¼ 997)
18 15
13 9
13 8
10 5
8 7
8 7
8 5
4 2
3 2
d reported for teriﬂunomide 14 mg or 7 mg atZ2% higher
TOPIC studies.
2373
Table IV. Routine monitoring and counseling recommended before initiation of teriflunomide and during
therapy
Before Initiation of Teriﬂunomide During Teriﬂunomide Treatment
Measure transaminase and bilirubin concentrations
(within 6 months before starting therapy)
Monitor ALT concentrations at least monthly
(for 6 months)
Exclude pregnancy and conﬁrm use of reliable
contraception; counsel patients on potential
for serious fetal risk
Check blood pressure periodically
Obtain complete blood count (within 6 months
before starting therapy)
Counsel patients to continue use of reliable
contraception during therapy
Screen for latent tuberculosis infection
Check baseline blood pressure
ALT ¼ alanine aminotransferase.
Clinical TherapeuticsTeriﬂunomide safety assessments and recommen-
dations in the US prescribing information were in-
formed by leﬂunomide postmarketing experience, data
from teriﬂunomide preclinical studies and clinical
trials, and from implications of the known immuno-
modulatory mechanism of action of teriﬂunomide.Routine Measures before Initiation of
Teriflunomide Therapy
Rare cases of severe liver injury in the postmarket-
ing setting were documented in patients treated with
leﬂunomide, and monitoring requirements for hepatic
enzymes were included in the teriﬂunomide prescrib-
ing information. Measurements of serum transami-
nase and bilirubin concentrations should be obtained
within 6 months of starting teriﬂunomide treatment.
Teriﬂunomide should not normally be given to pa-
tients with pre-existing acute or chronic liver disease
or patients with a serum ALT concentration42 times
the upper limit of normal before treatment initiation.
Data from animal studies suggest that teriﬂuno-
mide may be associated with teratogenicity. Pregnancy
must be avoided in women of childbearing potential
who are taking teriﬂunomide, and the use of reliable
contraception should be conﬁrmed with the patient.
Before treatment, pregnancy should be excluded, and
patients should be counseled fully on the potential for
serious fetal risk. Men not wishing to father a child
and their female partners should use reliable
contraception.2374Rare cases of pancytopenia, agranulocytosis, and
thrombocytopenia were reported in the postmarketing
setting with leﬂunomide, although no case of severe
pancytopenia was reported for teriﬂunomide. On the
basis of observed reductions in lymphocytes and
neutrophils in clinical trials with teriﬂunomide,
a complete blood count should be obtained within
6 months of starting treatment with teriﬂunomide.
Patients with active infection should not start
teriﬂunomide treatment until resolution of the infec-
tion. Cases of tuberculosis were observed in clinical
studies with teriﬂunomide. Before initiating teriﬂuno-
mide therapy, patients should be screened with
a tuberculin skin test or blood test for latent
tuberculosis infection, and patients with a positive
result should be treated according to standard
medical practice before teriﬂunomide treatment is
initiated.
Small increases in blood pressure were observed in
teriﬂunomide studies. Blood pressure should be
checked before the start of teriﬂunomide treatment
and monitored thereafter.Routine Measures during Teriflunomide Therapy
Serum ALT concentrations should be monitored at
least monthly for 6 months after treatment initiation;
additional monitoring should be considered if teriﬂu-
nomide is administered with other potentially hepato-
toxic drugs or if a patient develops symptoms
suggestive of hepatic dysfunction.Volume 37 Number 10
A.E. MillerMale and female patients should be counseled to
continue use of reliable contraception during therapy. If
pregnancy does occur during treatment, teriﬂunomide
should be discontinued immediately, and the acceler-
ated elimination procedure described in the next section
should be initiated until teriﬂunomide plasma concen-
trations are o0.02 μg/mL, a concentration at which
minimal risk to the fetus is expected. For male patients
who wish to father a child after commencing therapy,
teriﬂunomide should be discontinued, and the acceler-
ated drug elimination procedure should be imple-
mented.
Blood pressure should be checked periodically, and
any cases of elevated blood pressure should be
managed appropriately.
Accelerated Elimination Procedure
Teriﬂunomide is eliminated slowly from plasma,
taking an average of 8 months to decline to plasma
concentrations o0.02 mg/mL. Elimination of teriﬂuno-
mide from plasma can be accelerated by the admin-
istration of cholestyramine (8 g or 4 g TID) or activated
charcoal (50 g BID), which results in a498% decrease
in teriﬂunomide plasma concentration over 11 days
(Figure 5). The recommended elimination procedureTe
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Figure 5. Teriflunomide plasma concentrations
after an accelerated elimination pro-
cedure. A loading dose of terifluno-
mide (70 mg/d for 3–4 days) was
administered to achieve steady state
rapidly; this was followed by a main-
tenance dose of teriflunomide 14 mg/d
for 8 to 11 days. Cholestyramine
(8 g or 4 g, TID) or activated charcoal
(50 g, BID) was administered orally
for 11 days after teriflunomide treat-
ment. Adapted with permission.17
October 2015with the use of 8 g cholestyramine is more efﬁcient than
the lower dose; however, in cases of poor tolerability,
the 4-g dose may be considered.18 Dosing does not
need to take place on consecutive days unless an urgent
lowering of teriﬂunomide plasma concentration is
desired. Situations in which accelerated elimination of
teriﬂunomide should also be considered are listed in
Table V.
Pharmacokinetics
A population pharmacokinetic (PK) analysis in
healthy volunteers and patients with MS found that
the median half-life of teriﬂunomide after repeated
oral dosing of 14 mg and 7 mg is 19 and 18 days,
respectively. With daily dosing, steady-state concen-
trations are reached after 3 months. No clinically
signiﬁcant impact of food was found on the PK proﬁle
of teriﬂunomide; therefore, teriﬂunomide can be taken
with or without food.
Moreover, mild and moderate hepatic impairment
and severe renal impairment had no impact on the PK
proﬁle of teriﬂunomide. Consequently, no dose adjust-
ment is necessary in patients with these conditions.1,19,20
Drug–Drug Interactions
In vitro studies found that teriﬂunomide is not
metabolized by cytochrome P450 (CYP) or ﬂavin
monoamine oxidase enzymes, thereby limiting the
potential for interactions with many co-administered
drugs. However, teriﬂunomide may affect the expo-
sure to concomitantly administered drugs metabolized
by CYP2C8, CYP1A2, and organic anion transporter
(OAT) 3. Teriﬂunomide also inhibits the action of
breast cancer resistance protein and OAT peptides B1
and B3 (OATP1B1/B3) in vivo. Recommendations for
patients receiving teriﬂunomide and agents metabo-
lized by these agents and for patients receiving
warfarin or ethinylestradiol and levonorgestrel are
summarized in Table VI.
The effects of co-administration of teriﬂunomide
with antineoplastic or immunosuppressive MS
therapies are not yet evaluated. No safety concerns
were revealed during concomitant administration of
teriﬂunomide with other immunomodulating thera-
pies in Phase II combination studies for up to 1 year
(interferon-β, glatiramer acetate), but the long-term
safety proﬁle of these combinations in the treatment
of MS is not established.1,21,22 Co-administration of
teriﬂunomide with leﬂunomide is contraindicated.12375
Table V. Teriflunomide contraindications, warnings, and precautions in US prescribing information
Warnings and Precautions Rationale
Severe hepatic impairment Leﬂunomide/teriﬂunomide
clinical trials
Patients who are pregnant or women of
childbearing potential not using reliable
contraception (pregnancy category X)
Leﬂunomide/teriﬂunomide
preclinical toxicology
Co-administration of leﬂunomide Leﬂunomide/
immunomodulation
Warnings and precautions Rationale Recommendations While on Teriﬂunomide
Hepatotoxicity* Leﬂunomide/teriﬂunomide
clinical trials
Discontinue teriﬂunomide if drug-induced liver injury is
suspected; start accelerated elimination procedure,
and monitor liver tests weekly until normalized
Risk of teratogenicity*/use in women
of childbearing potential
Leﬂunomide/teriﬂunomide
preclinical toxicology
In patients who become pregnant/wish to become pregnant,
discontinue teriﬂunomide immediately; start accelerated
drug elimination until plasma concentration
o0.02 μg/mL reached
Because it is not known whether teriﬂunomide is present in
breast milk, counsel patients on whether to continue
teriﬂunomide or breastfeed; they should not do both
Concomitant use with immunosuppressive
or immunomodulating therapies
Leﬂunomide/
immunomodulation
If decision is made to switch from teriﬂunomide to another
DMT, monitor for hematologic toxicity and potential
rebound of disease
Accelerated elimination procedure Leﬂunomide/teriﬂunomide
clinical trials
Accelerated elimination of teriﬂunomide should be
implemented after discontinuation of teriﬂunomide in cases
in which: (1) pregnancy occurs during teriﬂunomide
therapy, (2) a patient taking teriﬂunomide wishes to
become pregnant or father a child, (3) drug-induced liver
(continued)
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Table V. (continued).
Warnings and Precautions Rationale
injury is suspected, or (4) clinically signiﬁcant toxicity
emerges
Bone marrow effects/immunosuppression
potential/infections
Leﬂunomide/teriﬂunomide
immunomodulation
Check complete blood count within 6 months before
starting therapy; base further monitoring on symptoms of
bone marrow suppression
Peripheral neuropathy Leﬂunomide/teriﬂunomide
clinical trials
If peripheral neuropathy is suspected, consider discontinuing
teriﬂunomide and implementing accelerated elimination
Skin reactions Leﬂunomide† In cases of Stevens-Johnson syndrome or toxic epidermal
necrolysis, discontinue teriﬂunomide and implement accelerated
elimination
Blood pressure increase Leﬂunomide/teriﬂunomide
clinical trials
Manage elevated blood pressure appropriately
Respiratory effects Leﬂunomide† Consider teriﬂunomide discontinuation in cases of new onset
or worsening pulmonary symptoms such as cough and
dyspnea ( fever); if discontinuation is necessary, consider
implementing accelerated elimination
DMT ¼ disease-modifying therapy.
*The US prescribing information contains a Boxed Warning for hepatotoxicity and risk of teratogenicity.
†Reported only in patients with rheumatoid arthritis receiving leﬂunomide. A similar risk would be expected for teriﬂunomide.
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Table VI. Co-administration of teriflunomide with other drugs
Drug Category (Examples) Effect Recommendation While on Teriﬂunomide
CYP1A2 substrates (caffeine, duloxetine,
alosetron, theophylline, tizanidine)
18% decrease in caffeine Cmax Monitor patients receiving a concomitant
CYP1A2 substrate55% decrease in caffeine AUC
CYP2C8 substrates (repaglinide, paclitaxel,
pioglitazone, rosiglitazone)
1.7-fold increase in repaglinide Cmax
2.4-fold increase in repaglinide AUC
Monitor patients receiving a concomitant
CYP2C8 substrate
CYP2C9 substrate (warfarin) 25% decrease in peak INR Monitor INR closely
Combined oral contraceptives
(ethinylestradiol/levonorgestrel)
Increase in ethinylestradiol Cmax and
AUC0–24 (1.58-fold increase and
1.54-fold increase, respectively)
Consider type or dose of oral contraceptive
Increase in levonorgestrel Cmax and AUC0–24
(1.33-fold increase and 1.41-fold
increase, respectively)
OAT3 substrates (cefaclor, cimetidine,
ciproﬂoxacin, penicillin G, ketoprofen,
furosemide, methotrexate, zidovudine)
Inhibition of OAT3 by teriﬂunomide
in vivo
Monitor patients receiving a concomitant
OAT3 substrate
Adjust dose of OAT3 substrate if required
OATP family (atorvastatin, nateglinide,
pravastatin, repaglinide, and
simvastatin, methotrexate, rifampin)
Inhibition of OATP1B1/1B3 by
teriﬂunomide in vivo
Monitor patients closely for signs and symptoms
of increased exposures to concomitant
OATP1B1/1B3 substrates
Consider reducing dose of OATP family drugs
Dose of rosuvastatin should not exceed 10 mg
once daily
BCRP substrates (mitoxantrone) Inhibition of BCRP by teriﬂunomide
in vivo
Monitor patients closely for signs and symptoms
of increased exposures to concomitant
BCRP substrates
Consider reducing dose of BRCP substrates
BCRP ¼ breast cancer resistance protein; CYP ¼ cytochrome P450; INR ¼ international normalized ratio; OAT ¼ organic anion transporter; OATP ¼ organic anion
transporting peptide.
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A.E. MillerSUMMARY
Teriﬂunomide is a once-daily oral treatment option
for adults with RMS, and data from 4 placebo-
controlled, randomized trials support its use in these
patients. The 14-mg dose had a signiﬁcant impact on
3 key measures of MS disease activity: risk of
sustained disability progression, ARR, and various
MRI measures. The 7-mg dose also exhibited signiﬁ-
cant improvements on relapse rate and MRI out-
comes and a numerical improvement on the risk of
disability progression compared with placebo. Both
teriﬂunomide doses had a similar safety proﬁle and
tolerability. Pretreatment clinical and laboratory eval-
uations and on-treatment monitoring will facilitate
timely identiﬁcation of any potential safety proﬁle
concerns that arise in patients treated with teriﬂuno-
mide. In conclusion, these data suggest that teriﬂu-
nomide is an effective treatment option for patients
with RMS with a favorable beneﬁt–risk proﬁle and a
therapeutic alternative for those patients unable to
tolerate their past or current disease-modifying
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